CORT-108297

CORT-108297

Clinical data
Other names	CORT108297; ADS-108297; ADS108297
Routes of administration	Oral[1]
Drug class	Antiglucocorticoid; Selective glucocorticoid receptor modulator
ATC code	None
Identifiers
IUPAC name (4aR)-4a-(ethoxymethyl)-1-(4-fluorophenyl)-6-[4-(trifluoromethyl)phenyl]sulfonyl-4,5,7,8-tetrahydropyrazolo[5,4-g]isoquinoline
CAS Number	1018679-79-2
PubChem CID	44454750
ChemSpider	23322313
UNII	A17W0640NB
ChEMBL	ChEMBL271220
CompTox Dashboard (EPA)	DTXSID70144304
Chemical and physical data
Formula	C26H25F4N3O3S
Molar mass	535.56 g·mol^−1
3D model (JSmol)	Interactive image
SMILES CCOC[C@]12CC3=C(C=C1CCN(C2)S(=O)(=O)C4=CC=C(C=C4)C(F)(F)F)N(N=C3)C5=CC=C(C=C5)F
InChI InChI=1S/C26H25F4N3O3S/c1-2-36-17-25-14-18-15-31-33(22-7-5-21(27)6-8-22)24(18)13-20(25)11-12-32(16-25)37(34,35)23-9-3-19(4-10-23)26(28,29)30/h3-10,13,15H,2,11-12,14,16-17H2,1H3/t25-/m1/s1 Key:SLKURXRZHJOZOD-RUZDIDTESA-N

CORT-108297, also known as ADS-108297, is a nonsteroidal selective glucocorticoid receptor modulator (SEGRM) with mixed glucocorticoid and antiglucocorticoid actions which is under development for the treatment of Alzheimer's disease, cognition disorders, memory disorders, and post-traumatic stress disorder (PTSD).^[1][2][3][4] It was also being developed for treatment of other psychiatric disorders and weight gain, but development for these indications was discontinued.^[1] The drug is taken by mouth.^[1] As of November 2022, CORT-108297 is in phase 2 clinical trials for the aforementioned active indications.^[1][2]

See also

• Dagrocorat (PF-00251802)
• Dazucorilant (CORT-113176)
• Miricorilant (CORT-118335)
• Relacorilant (CORT-125134)

References

1. "CORT 108297". AdisInsight. 29 November 2022. Retrieved 28 September 2025.
2. "Delving into the Latest Updates on CORT-108297 with Synapse". Synapse. 27 September 2025. Retrieved 28 September 2025.
3. Viho EM, Buurstede JC, Mahfouz A, Koorneef LL, van Weert LT, Houtman R, et al. (2019). "Corticosteroid Action in the Brain: The Potential of Selective Receptor Modulation". Neuroendocrinology. 109 (3): 266–276. doi:10.1159/000499659. PMC 6878852. PMID 30884490.
4. Lucafò M, Franzin M, Decorti G, Stocco G (May 2020). "A patent review of anticancer glucocorticoid receptor modulators (2014-present)". Expert Opinion on Therapeutic Patents. 30 (5): 313–324. doi:10.1080/13543776.2020.1740206. PMID 32148111.